Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Trial Profile

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Dolutegravir/lamivudine (Primary) ; Tenofovir alafenamide
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms ReNew
  • Most Recent Events

    • 17 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
    • 14 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top